HOME >> BIOLOGY >> NEWS
Consortium to create comprehensive tools for uncovering the functions of human, mouse genes

CAMBRIDGE, Mass., Thursday, March 15, 2005--Eleven leading biomedical organizations announced today the formation of a unique $18M, three-year public-private consortium to create a comprehensive library of gene inhibitors to be made available to the entire scientific community. Based on the method of RNA interference (RNAi), this library will give scientists worldwide the tools to knock down expression of virtually all human and mouse genes, accelerating the growth of basic knowledge of gene function in normal physiology and disease.

Called The RNAi Consortium (TRC), the collaborative effort is based at the Broad Institute of MIT and Harvard, and includes six MIT- and Harvard-associated research institutions and five international life sciences organizations.

The goal of TRC is to use the recently discovered RNAi mechanism to create widely applicable research reagents composed of short RNA hairpin sequences carried in lentiviral vectors. These can be used in a wide range of cellular and animal studies to discover the key genes underlying normal physiology and diseases including cancer, diabetes and immunological responses. TRC will not only create and validate these reagents, but will make them available to scientists worldwide through commercial and academic distributors.

TRC is based on a scientific collaboration among principal investigators at six Boston-area research institutions: Nir Hacohen (Massachusetts General Hospital, Harvard Medical School); William Hahn (Dana-Farber Cancer Institute, Harvard Medical School); Eric Lander (Broad Institute); David Root (Broad Institute); David Sabatini (Whitehead Institute for Biomedical Research [WIBR], Massachusetts Institute of Technology; Sheila Stewart (Washington University, formerly at WIBR), and Brent Stockwell (Columbia University, formerly at WIBR).

TRC also involves five member organizations: Pharmaceutical companies Bristol-Myers Squibb, Eli Lilly and Company, and Novartis;
'"/>

Contact: Michelle Nhuch
news@broad.mit.edu
617-252-1064
Whitehead Institute for Biomedical Research
16-Mar-2005


Page: 1 2 3 4

Related biology news :

1. Genome Canada, Gnome Qubec and Universit de Montral launch P3G Consortium and CARTaGENE Project
2. International Genomics Consortium, TGen to lead Biospecimen Core for Cancer Atlas pilot project
3. Consortium for Functional Glycomics awarded $40.7 million glue grant
4. Consortium seeks comment on gene expression roadmap
5. ORNL technologies win maximum Federal Laboratory Consortium awards
6. Newly created cancer stem cells could aid breast cancer research
7. MIT creates 3-D images of living cell
8. Not all embryonic stem cell lines are created equal
9. Researchers use adult stem cells to create soft tissue
10. Fusing imaging technologies creates synergy, helps diagnose heart disease accurately
11. Researchers create model of cancer-preventing enzyme, study how it works

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... Litmus Health , ... third-party assessment of the company’s security practices has been completed. The assessment deemed ... The comprehensive evaluation reviewed Litmus’ processes and systems, assessing them to see whether ...
(Date:8/26/2020)... , ... August 25, 2020 , ... ... manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, ... Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage ... Food and Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) ... severe COVID-19. Approval of this IND allows Sentien to initiate a Phase 1/2 ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... ... up to three different materials for use with CRM, neurostimulation, vascular, and related ... materials to meet specific design requirements, performance, and cost criteria; especially where solid ...
(Date:7/31/2020)... ... 2020 , ... eSource has long been touted as the solution to high ... eSource, the reasons it did not take off as quickly as people initially expected, ... is moving towards capturing data electronically for clinical trials and then repurposing it for ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... life sciences industry, today announced the release of its signature product called ... Science Liaisons (MSLs) and other field medical professionals. , Beacon helps ...
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery and catheter implantation, ... surgery is only the beginning of a successful study, while protecting and accessing the ... Gien, Global Head of Surgery from Envigo in a live webinar ...
Breaking Biology Technology:
Cached News: